Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel, Sequential Consolidation With Nab-paclitaxel Followed by Pembrolizumab and Concurrent Consolidation With Nab-paclitaxel and Pembrolizumab After Standard First-Line Induction Chemotherapy in Advanced NSCLC

Trial Profile

Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel, Sequential Consolidation With Nab-paclitaxel Followed by Pembrolizumab and Concurrent Consolidation With Nab-paclitaxel and Pembrolizumab After Standard First-Line Induction Chemotherapy in Advanced NSCLC

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Mar 2017 Planned End Date changed from 1 Aug 2019 to 1 Feb 2023.
    • 10 Mar 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Feb 2023.
    • 19 Sep 2016 Planned End Date changed from 1 Jun 2019 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top